The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year ...

The FDA approved the monoclonal antibody clesrovimab-cfor for the prevention of respiratory syncytial virus lower respiratory ...

Merck (MRK) stock is in focus as its Enflonsia RSV shot is cleared for infants in the U.S. in a market led by Sanofi (SNY) ...

The approval was based on data from the pivotal Phase IIb/III CLEVER trial which assessed a single dose of the antibody.

The CDC’s Advisory Committee on Immunization Practices is expected to meet later in June to issue recommendations for use.

The feud between Secret Lives of Mormon Wives costars Whitney Leavitt and Mikayla Matthews just got very messy, courtesy of ...

Merck’s Enflonsia will go up against Sanofi and AstraZeneca’s Beyfortus, which the partners plan to ship out early in the ...

Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...

Adelaide nurse and mother-of-two Deanne Tingey thought her little girl, Winter, was just suffering from a common cold.

MPV tends to hit hardest in young children, older adults and people with weakened immune systems. A virologist explains.